INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Cummings Keith Lamont sold PLRX

Chief Financial Officer · PLIANT THERAPEUTICS, INC. · Common Stock

Side
SELL
Value
$31K
Shares
24.0K
Price
$1.28
Executed
Jan 20, 2026
Disclosed
Jan 22, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 20 executedJan 22, 2026 disclosed

PLRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+5 / 25

    $31K reported value · 7.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PLRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    CL
    Cummings Keith LamontChief Financial Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    400.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    5
    KM
    Kuo MinnieChief Operating Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    300.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    5
    CL
    Cheung LilyChief Human Resource Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    300.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    5
    CB
    Coulie BernardDirector, President and CEO
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    1.23M sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    24
    CL
    Cheung LilyChief Human Resource Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$9,644
    7,534 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    27
    CB
    Coulie BernardDirector, President and CEO
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$114K
    89.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    24
    KM
    Kuo MinnieChief Operating Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$8,854
    6,917 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001746473-26-000012
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 20, 2026
    Published
    Jan 22, 2026
    Ingested by INSIDER
    Nov 5, 04:21 UTC
    Last re-read
    Nov 5, 04:21 UTC

    Extracted facts

    Filer
    Cummings Keith Lamont
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    PLIANT THERAPEUTICS, INC.
    Ticker
    PLRX
    Shares
    24.0K
    Price per share
    $1.28
    Value
    $30,723
    Execution date (reported)
    Jan 20, 2026
    Owned after transaction
    297.2K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 24.0K
    • Price: $1.28

    = $30,723

    What this establishes

    Cummings Keith Lamont filed this Form 4 reporting a open-market sale of PLRX on Jan 20, 2026. It became public on Jan 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Cummings Keith Lamontcik:0001809204
    Issuer
    PLIANT THERAPEUTICS, INC.cik:0001746473

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.